Acquisitions Catapult China Biologic Into Leading Biopharma Outfit; Position It For Global Competition With U.S., EU Players
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The chief executive officer of China Biologic Products Inc. said an aggressive acquisition strategy has helped transform the company into China's leading privately held provider of plasma-based biopharmaceuticals, and that the outfit is aiming to expand its geographical footprint across the globe
You may also be interested in...
Twin Acquisitions, China-wide Plasma Shortage, Boost Earnings For China Biologic
BEIJING - The leadership of China Biologic Products, the country's biggest privately held provider of plasma-based biopharmaceuticals, said that the acquisition of two competitors earlier this year helped elevate profits in the second quarter, and that the emergence of the A/H1N1 pandemic could bolster sales throughout the year
Twin Acquisitions, China-wide Plasma Shortage, Boost Earnings For China Biologic
BEIJING - The leadership of China Biologic Products, the country's biggest privately held provider of plasma-based biopharmaceuticals, said that the acquisition of two competitors earlier this year helped elevate profits in the second quarter, and that the emergence of the A/H1N1 pandemic could bolster sales throughout the year
China's New Legal Power To Limit Or Block Mergers Could Signal Challenges Ahead For Global Pharmaceutical Alliances
BEIJING - The Chinese Ministry of Commerce's wielding of a new Anti-Monopoly Law to block Coca-Cola's purchase of a local juice producer, and to impose severe restrictions on the combination of two other international businesses, could signal troubled times ahead for any global outfit operating in China that seeks to expand through a merger